REBEL EM is licensed under a
© 2022 REBEL EM. All rights reserved. | Disclaimer | Website by Innov8 Place.
Archive
Medical Category: Cardiovascular
The INSPIRATION Trial: Intermediate Dose Anticoagulation in Critically Ill Patients with COVID-19
Background: COVID-19 infection increases the risk of thrombosis due to multiple factors.(Rico-Mesa, 2020). Over the last 2 years, researchers have published 12 RCTs investigating various anticoagulation strategies among patients diagnosed with COVID-19 in multiple clinical settings. To date, only a multiplatform ...
Effect of Intra-Arrest Transport and eCPR on Neurologic Outcomes in Refractory OHCA
Background Information: Refractory out of hospital cardiac arrest (OHCA) is defined as prolonged cardiac arrest and cardiac arrest without return of spontaneous circulation (ROSC). In addition to an already morbid condition, the chances of these patients surviving drops below 5% ...
The ACTION Trial: DOACs in Hospitalized Patients with COVID-19
Background: Patients hospitalized with COVID-19 are at increased risk for both arterial and venous thromboembolic disease. Multiple recent trials have investigated the efficacy of therapeutic or standard prophylactic anticoagulation in preventing thrombotic complications among patients with COVID-19 in a variety ...
The MICHELLE Trial: Anticoagulation Post-Discharge in Patients Hospitalized Secondary to COVID-19
Background: Patients diagnosed with COVID-19 have an increased risk of thromboembolic events, including pulmonary embolism and deep vein thrombosis (DVT). In addition, COVID-19 patients with increased coagulation parameters such as D-dimer, fibrin degradation products, prothrombin time, and activated partial thromboplastin ...